Safety Concerns
Tysabri Side Effects Not as Serious as Projected
by Kevin Rippey on Nov.23, 2009, under Nanotech Company Info, Pharmaceuticals, Safety Concerns
Biogen and Elan’s (NASDAQ: ELN) multiple sclerosis drug Tysabri has been a subject of serious concern as a rare brain infection PML has been a known side effect of the drug. However, more recent reports have shown that the frequency as well as the severity of the side effect is not as grave as originally thought. In fact, initial estimates of the frequency of PML as a side effect was 1/1000. However, data collected over the past 4 years has shown that the frequency is closer to 1/2500.
Full Story: Here
Star Tribune “Nanotechnology: A Risky Frontier”
by Kevin Rippey on Nov.02, 2009, under Safety Concerns
Article in the Minneapolis Star Tribune addressing some of the more commonly understood risks of nanotech as well as the lack of legal clarity in the field. Article also discusses the EPA’s unwillingness to draw clear guidelines in an emerging tech space.
Full Story: Here
